Eli Lilly (LLY)
Develops cardiometabolic, cancer, immunology, and neuroscience medicines led by tirzepatide.
$1,147.89
vs last close−17.00 (−1.46%)
Something off on this page? Send us feedback.
Next report
Oct 29, 26
in 37 days
EPS estimate
$9.85
Revenue estimate
$22.19B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26Apr '26Aug '26Oct '26
Reported$5.32$3.34$6.31$7.02$7.54$8.55$8.38Pending
Estimate$5.03$3.26$5.60$5.69$6.91$6.97$6.40$9.85
Surprise+5.8%+2.5%+12.7%+23.4%+9.1%+22.7%+30.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26Apr '26Aug '26Oct '26
Reported$13.53B$12.73B$15.56B$17.60B$19.29B$19.80B$22.97BPending
Estimate—$12.67B$14.70B$16.05B$17.94B$17.82B$20.82B$22.19B
Surprise—+0.5%+5.8%+9.6%+7.5%+11.1%+10.3%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $9.25 | — | — |
| Sep 2027 | $11.94 | — | — |
| Jun 2027 | $11.28 | — | — |
| Mar 2027 | $9.80 | — | — |
| Dec 2026 | $9.96 | — | — |
| Oct 2026 | $9.85 | — | — |
| Aug 2026 | $6.40 | $8.38 | +30.9% |
| Apr 2026 | $6.97 | $8.55 | +22.7% |
| Feb 2026 | $6.91 | $7.54 | +9.1% |
| Oct 2025 | $5.69 | $7.02 | +23.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Aug 2021 | |||
| Apr 2021 | |||
| Jan 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $9.25 | — | — | $20.03B | — | — | — |
| Sep 2027 | $11.94 | — | — | $25.52B | — | — | — |
| Jun 2027 | $11.28 | — | — | $24.83B | — | — | — |
| Mar 2027 | $9.80 | — | — | $22.30B | — | — | — |
| Dec 2026 | $9.96 | — | — | $23.18B | — | — | — |
| Oct 29, 2026 | $9.85 | — | — | $22.19B | — | — | — |
| Aug 5, 2026 | $6.40 | $8.38 | +30.9% | $20.82B | $22.97B | +10.3% | +4.9% |
| Apr 30, 2026 | $6.97 | $8.55 | +22.7% | $17.82B | $19.80B | +11.1% | +9.8% |
| Feb 4, 2026 | $6.91 | $7.54 | +9.1% | $17.94B | $19.29B | +7.5% | +10.3% |
| Oct 30, 2025 | $5.69 | $7.02 | +23.4% | $16.05B | $17.60B | +9.6% | +3.8% |
| Aug 7, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 6, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Aug 8, 2024 | |||||||
| Apr 30, 2024 | |||||||
| Feb 6, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 8, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Feb 2, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 4, 2022 | |||||||
| Apr 28, 2022 | |||||||
| Feb 3, 2022 | |||||||
| Oct 26, 2021 | |||||||
| Aug 3, 2021 | |||||||
| Apr 27, 2021 | |||||||
| Jan 29, 2021 | |||||||
| Oct 27, 2020 | |||||||
| Jul 30, 2020 | |||||||
| Apr 23, 2020 | |||||||
| Jan 30, 2020 | |||||||
| Oct 23, 2019 | |||||||
| Jul 30, 2019 | |||||||
| Apr 30, 2019 | |||||||
| Feb 6, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Jul 24, 2018 | |||||||
| Apr 24, 2018 | |||||||
| Jan 31, 2018 | |||||||
| Oct 24, 2017 | |||||||
| Jul 25, 2017 | |||||||
| Apr 25, 2017 | |||||||
| Jan 31, 2017 | |||||||
| Oct 25, 2016 | |||||||
| Jul 26, 2016 | |||||||
| Apr 26, 2016 | |||||||
| Jan 28, 2016 | |||||||
| Oct 22, 2015 | |||||||
| Jul 23, 2015 |